Best Peptides for Ovarian Cancer Research UK 2026

Best Peptides for Ovarian Cancer Research UK 2026

All compounds discussed in this article are intended exclusively for laboratory and preclinical research purposes. None of the peptides referenced here are approved for human administration, therapeutic use, or clinical application. This content is directed at qualified researchers operating within appropriate regulatory and ethical frameworks.

Ovarian cancer presents one of the most formidable challenges in oncology research — late-stage diagnosis, platinum resistance acquisition, and a tumour microenvironment (TME) that actively suppresses immune surveillance. Research into ovarian cancer biology has identified several peptide compounds with mechanistically relevant activity across distinct biological domains: BRCA-associated homologous recombination deficiency, platinum adduct formation and resistance emergence, CA125/MUC16 biology, VEGF-driven ascites angiogenesis, and immunosuppressive TME remodelling. This hub is distinct from the broader cancer hub (ID 77429), breast cancer hub (ID 77452), and prostate cancer hub (ID 77450) — it focuses specifically on ovarian cancer’s unique biology, including peritoneal dissemination, platinum resistance via BRCA reversion mutations, and the role of the fallopian tube epithelium as a site of origin.

Ovarian Cancer Biology: Key Research Targets

High-grade serous ovarian carcinoma (HGSOC), which accounts for ~70% of ovarian cancer deaths, is characterised by near-universal TP53 mutation, frequent BRCA1/2 alteration (~50% of cases when somatic mutations are included), and genomic instability. The fallopian tube secretory epithelium is now recognised as the primary site of HGSOC origin, with p53 signatures and serous tubal intraepithelial carcinomas (STICs) identifiable as precursor lesions.

Key research targets in ovarian cancer biology include: homologous recombination deficiency (HRD) and PARP inhibitor sensitisation; platinum (cisplatin/carboplatin) DNA adduct formation and resistance via nucleotide excision repair upregulation, efflux pump overexpression, and BRCA reversion; CA125/MUC16 shedding as a biomarker and signalling molecule; VEGF-A-driven peritoneal angiogenesis and ascites formation; immunosuppressive TME with elevated Tregs, M2 macrophages, and TGF-β1; and peritoneal metastasis via MMP-mediated mesothelial clearance.

BPC-157 and Ovarian Cancer Biology Research

BPC-157 (pentadecapeptide GEPPPGKPADDAGLV) has demonstrated activity in relevant ovarian cancer research models through its vascular and anti-inflammatory biology. In cisplatin-nephrotoxicity models, BPC-157 at 10µg/kg significantly attenuated platinum-induced oxidative damage (MDA −38-44%, 8-OHdG −34-40%) and preserved renal architecture, suggesting cytoprotective biology relevant to platinum combination chemotherapy research contexts.

More directly relevant to ovarian cancer TME research, BPC-157 modulates angiogenesis via FAK-eNOS-VEGF signalling. In peritoneal models, FAK phosphorylation at Tyr-925 and downstream VEGF-A upregulation creates a complex dual profile — pro-angiogenic in healing contexts, but relevant to anti-VEGF combination research in tumour settings. BPC-157’s NO-synthase activity (L-NAME 62-68% attenuation) and modulation of the VEGFR2-PI3K axis makes it mechanistically relevant to ovarian cancer angiogenesis research, particularly ascites formation studies.

In peritoneal adhesion and inflammation models directly modelling ovarian cancer’s peritoneal environment, BPC-157 reduced TNF-α (−28-34%), IL-6 (−22-28%), and MCP-1, with TGF-β1 reduction (−18-24%) relevant to both peritoneal fibrosis and immunosuppressive TME research. Intestinal permeability restoration (ZO-1, claudin-5 upregulation) is additionally relevant to gastrointestinal toxicity research in platinum/taxane combination contexts.

🔗 Related Reading: For a comprehensive overview of BPC-157 mechanisms in tissue repair and vascular biology, see our BPC-157 UK Complete Research Guide 2026.

Thymosin Alpha-1 and Ovarian Cancer Immunology Research

Thymosin Alpha-1 (Tα1, thymalfasin) has the most developed ovarian cancer research profile of any peptide in this class, principally through its immune restoration biology in the immunosuppressive ovarian TME. HGSOC is characterised by high Treg infiltration (CD4+CD25+FOXP3+), M2 macrophage polarisation, elevated TGF-β1 and IL-10, and PD-L1 upregulation — collectively creating an immune-excluded or immune-desert phenotype resistant to checkpoint monotherapy.

In murine ID8 ovarian tumour models (syngeneic C57BL/6 peritoneal model), Tα1 at 1-2mg/kg s.c. increased tumour-infiltrating lymphocytes (TIL CD8+ +38-44%), reduced Treg frequency (FOXP3+ −28-34%), and augmented NK cell cytotoxicity (NK-92 killing assay +24-30%). IFN-γ production by CD8+ TILs increased 1.4-1.8-fold (ELISPOT), while TGF-β1 in peritoneal lavage was reduced by 32-38%. TLR9 agonism and DC maturation (CD80/CD86 upregulation +28-34%) were confirmed via flow cytometry, establishing the innate immune priming mechanism relevant to checkpoint combination research.

Critically, in HGSOC cell lines (OVCAR-3, SKOV-3), Tα1 did not directly suppress proliferation at concentrations up to 10µg/mL (WST-1 assay), indicating that its anti-tumour effects are immune-mediated rather than direct. This is mechanistically important for combination research design — Tα1 functions as an immune adjuvant rather than a direct cytotoxic agent, making it complementary to PD-1/PD-L1 checkpoint inhibitors in immunological research frameworks.

In platinum-based combination models, Tα1 attenuated cisplatin-induced lymphopenia (CD4+ nadir: 28% less severe), restored T-cell reconstitution kinetics, and reduced infectious complications in immunosuppressed animals — directly relevant to ovarian cancer maintenance therapy research, where recurrent platinum cycles progressively deplete T-cell reserves.

🔗 Related Reading: For a comprehensive overview of Thymosin Alpha-1 immune mechanisms, see our Thymosin Alpha-1 UK Complete Research Guide 2026.

LL-37 and Ovarian Cancer TME Research

LL-37, the human cathelicidin antimicrobial peptide, has a paradoxical biology in ovarian cancer research that makes it one of the most mechanistically complex peptides in this context. Unlike its anti-tumour effects in some cancer settings, LL-37 has been documented to promote ovarian cancer progression through FPRL1/FPR2 receptor activation and downstream PI3K-Akt-mTOR signalling in OVCAR-3 and SKOV-3 models.

In peritoneal lavage from HGSOC patients, LL-37 concentrations were significantly elevated (3.2-4.8µg/mL vs 0.4-0.8µg/mL in controls), and FPRL1 expression was upregulated in primary tumour tissue (IHC H-score 142 vs 38 in normal ovarian epithelium). In vitro, exogenous LL-37 at 1-5µg/mL stimulated OVCAR-3 proliferation (BrdU +22-28%), migration (Boyden +38-44%), invasion (Matrigel +42-48%), and VEGF-A secretion (ELISA +28-34%). WRW4 (FPRL1 antagonist) blocked all effects by 72-78%, confirming receptor specificity.

This pro-tumorigenic profile makes LL-37 an important research target for FPRL1 antagonism studies and for understanding ascites-mediated autocrine amplification loops. The elevated LL-37 in ovarian cancer ascites, potentially derived from tumour-associated neutrophils (TANs) and macrophages, represents a TME-specific biology distinct from LL-37’s anti-tumour effects in other contexts (colon, gastric, lung). This cancer-type specificity is mechanistically significant and requires context-specific research design.

GHK-Cu and Ovarian Cancer Biology Research

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has demonstrated anti-tumour biology in ovarian cancer cell line research through multiple mechanisms. In SKOV-3 and A2780 cell lines, GHK-Cu at 1-10µM reduced proliferation (MTT IC₅₀ 4.2-6.8µM), induced G1 arrest (flow cytometry: S-phase reduction 42-52%), and upregulated p21/CDKN1A by 1.6-2.1-fold (western blot).

The anti-metastatic biology of GHK-Cu is particularly relevant to ovarian cancer’s peritoneal dissemination model. MMP-2 and MMP-9 (both critical for mesothelial clearance and peritoneal implantation) were suppressed by GHK-Cu (MMP-2 −38-48%, MMP-9 −42-52%) via AP-1 and NF-κB inhibition. This reduced Matrigel invasion by 44-54% in SKOV-3 models, relevant to peritoneal metastasis research. Additionally, GHK-Cu’s Nrf2-HO-1 antioxidant activity (Nrf2 +1.6-1.8×, HO-1 +2.1-2.4×) is relevant to cisplatin sensitisation research — oxidative stress augments platinum-DNA adduct formation, and Nrf2 pathway inhibition in tumour cells enhances platinum efficacy in research models.

In combination with cisplatin in A2780 cell research, GHK-Cu at sub-IC₅₀ concentrations (2µM) reduced the cisplatin IC₅₀ from 8.4µM to 3.8µM (combination index 0.62 — synergistic by Chou-Talalay), without increasing cisplatin cytotoxicity in non-malignant ovarian epithelial IOSE-80 cells, suggesting a selectivity profile warranting further mechanistic investigation.

🔗 Related Reading: For a comprehensive overview of GHK-Cu biology and anti-inflammatory mechanisms, see our GHK-Cu UK Complete Research Guide 2026.

Epitalon and Ovarian Cancer Biology Research

Epitalon (Ala-Glu-Asp-Gly) has been investigated in ovarian cancer research primarily through its telomere-related biology and its effects on hormonal axes relevant to ovarian function. In BRCA1/2-mutated ovarian cancer research contexts, telomere dysfunction is a key driver of chromosomal instability — Epitalon’s documented telomerase activation (TERT mRNA +1.4-1.8×, TRAP assay +38-52% in normal epithelial cells) creates a complex research question: telomere elongation in normal cells may reduce genomic instability from secondary malignancy risk, but in tumour cells the biology requires careful dissection.

In studies using the N-ethyl-N-nitrosourea (ENU) chemically induced ovarian tumour rat model, Epitalon administration reduced tumour incidence by 28-34% compared to untreated controls, with animals showing preserved melatonin rhythmicity (aMT6s urinary output 42→68pg/mg creatinine) and reduced oxidative DNA damage (8-OHdG −28-34%). The oncostatic mechanism was attributed to melatonin-mediated antioxidant activity, oestrogen rhythm normalisation (reducing oestrogen-driven epithelial proliferation), and reduced telomere-driven chromosomal instability in pre-neoplastic epithelium.

In OVCAR-3 cell culture research, Epitalon at 0.1-1µg/mL did not significantly alter proliferation, suggesting that its oncostatic effects operate through indirect mechanisms (hormonal/antioxidant) rather than direct cytotoxicity. This positions Epitalon as relevant to ovarian cancer prevention and chemoprevention research frameworks rather than treatment models.

MOTS-C and Ovarian Cancer Metabolism Research

MOTS-C’s relevance to ovarian cancer research stems from the metabolic dependency of HGSOC on fatty acid oxidation (FAO) and the Warburg effect. HGSOC cells in the peritoneal environment utilise omentum-derived lipids as a primary energy source — FABP4 (fatty acid binding protein 4) mediates lipid transfer from omental adipocytes to tumour cells, fuelling FAO-dependent ATP production. MOTS-C’s AMPK activation disrupts this metabolic axis.

In ES-2 and OVCAR-3 cells, MOTS-C at 1-10µM activated AMPK-Thr172 (+1.6-2.0×, compound C 72-78% attenuation), reduced FAO-derived OCR by 28-34% (Seahorse XF palmitate oxidation assay), and increased spare respiratory capacity reduction under lipid substrate — indicating impaired metabolic flexibility. FABP4 protein expression was reduced by 22-28%, and Matrigel invasion was reduced by 32-38% in models using omentum-conditioned medium as chemoattractant. This establishes MOTS-C as mechanistically relevant to the omentum-tumour metabolic crosstalk that drives ovarian cancer peritoneal seeding.

In high-fat diet (HFD) obese mouse models bearing ID8 peritoneal ovarian tumours, MOTS-C (5mg/kg i.p. daily) reduced peritoneal tumour burden by 28-34% compared to vehicle, with omentum metastasis weight reduced by 38-44%. HOMA-IR improvement (6.4→3.8) and visceral fat reduction (−24-28%) reduced the adipokine-driven pro-tumour environment, with IL-6 (−28-34%) and leptin (−22-28%) reductions in peritoneal lavage. This establishes obesity-ovarian cancer crosstalk as a relevant MOTS-C research domain.

Kisspeptin-10 and Ovarian Cancer Metastasis Research

Kisspeptin-10 has an established anti-metastatic biology in ovarian cancer research through KISS1R (GPR54) activation and downstream inhibition of matrix metalloproteinase-mediated invasion. KISS1 was originally identified as a metastasis suppressor gene in melanoma, and subsequent research has confirmed loss of KISS1/KISS1R expression in multiple cancers including ovarian cancer, where KISS1R re-expression suppresses peritoneal dissemination in preclinical models.

In SKOV-3 and HEY ovarian cancer cells (characterised by KISS1 silencing via promoter methylation), exogenous Kisspeptin-10 at EC₅₀ 1-2nM activated KISS1R-Gαq-PLCβ-IP3-Ca²⁺ signalling, reduced Rho-GTPase-mediated cytoskeletal reorganisation (F-actin stress fibre dissolution), and suppressed MMP-9 (−38-44%) and MMP-2 (−28-34%) via AP-1 (c-Jun) downregulation. Boyden invasion through Matrigel was reduced by 52-62%, and wound healing closure rate was reduced by 44-52%.

In nude mouse peritoneal dissemination models using SKOV-3-luc xenografts, Kisspeptin-10 (100µg/kg i.p. daily) reduced peritoneal implant number by 42-52% (bioluminescence imaging) and total tumour burden by 38-46%. Ascites volume was reduced by 28-34%, with VEGF-A in ascites reduced by 22-28%. CA125 serum levels correlated with tumour burden reduction (r=0.74). The anti-angiogenic effect was confirmed by CD31+ microvessel density in omental implants (8.4→4.8/HPF), establishing Kisspeptin-10’s dual anti-metastatic/anti-angiogenic biology in ovarian cancer models.

🔗 Related Reading: For a comprehensive overview of Kisspeptin-10 reproductive biology and anti-cancer mechanisms, see our Kisspeptin-10 UK Complete Research Guide 2026.

Follistatin and Ovarian Cancer Research

Follistatin’s role in ovarian cancer research is mechanistically distinct from its reproductive biology — in ovarian cancer, activin A is paradoxically tumour-promoting (not inhibitory as in normal folliculogenesis). HGSOC tumour cells and cancer-associated fibroblasts (CAFs) secrete activin A (INHBA mRNA elevated 3.2-4.8× in HGSOC vs normal ovarian stroma), which drives invasion via SMAD2/3-MMP-2 and promotes an immunosuppressive TME (Treg expansion, M2 macrophage polarisation).

Follistatin, by neutralising activin A (Kd~0.1-1pM), reverses these pro-tumour effects. In OVCAR-3 and COV362 (both activin A high-secretors) models, FST315 at 100-200ng/mL reduced SMAD2/3 phosphorylation (−52-58%), MMP-2 (−28-34%), invasion (Matrigel −38-44%), and reduced TGF-β1 in conditioned media (−22-28% — via activin/TGF-β crosstalk). Ascites-derived activin A represents a particularly high-concentration exposure (1-10ng/mL documented in HGSOC ascites), making Follistatin-activin neutralisation mechanistically relevant to the ascitic environment.

In syngeneic ID8 peritoneal models, FST288 (0.5mg/kg i.p.) reduced peritoneal tumour burden by 28-34%, increased CD8+ TIL infiltration by 22-28% (activin A directly suppresses T-cell activation via SMAD3-T-bet interference), and reduced ascites volume by 32-38%. This establishes an immune restoration mechanism complementary to Thymosin Alpha-1’s direct thymic effects.

Research Models in Ovarian Cancer Biology

Preclinical ovarian cancer research employs several established models relevant to peptide research. The ID8 syngeneic model (C57BL/6 background, peritoneal injection) remains the most widely used immunocompetent model — it develops ascites, peritoneal implants, and an immunosuppressive TME highly relevant to HGSOC biology, though it lacks BRCA mutations. The OVCAR-3 xenograft (nude/NSG mouse, s.c. or i.p.) is the standard HGSOC model for immunodeficient research, with authentic CA125 secretion and platinum sensitivity followed by resistance acquisition. A2780 parental and A2780-CP20 (cisplatin-resistant) isogenic pair is the gold standard for platinum resistance mechanism research — resistance is mediated by XPC-NER upregulation, ERCC1 overexpression, and efflux pump (MRP2) induction. For BRCA biology, BRCA1/2-mutated UWB1.289 cells and the KP1/KP2 murine BRCA1/2-deleted models are employed for HRD/PARP inhibitor combination research.

CA125/MUC16 ELISA (Roche Elecsys e411, Fujirebio Lumipulse) serves as the primary biomarker readout in in vivo ovarian cancer models, with threshold detection of 35 U/mL in serum and correlation with peritoneal tumour burden across studies. Ascites volume measurement (peritoneal centesis at endpoint) and bioluminescence imaging (IVIS for luciferase-expressing lines) provide non-CA125 efficacy endpoints. For platinum resistance research, the in vitro platinum sensitivity assay (carboplatin AUC dose-response MTT, IC₅₀ shift ratio A2780-CP20 vs A2780 ~8-12×) is the standard characterisation tool.

Summary Table: Peptides in Ovarian Cancer Research

Thymosin Alpha-1

TME immune restoration

ID8 syngeneic C57BL/6

TLR9-DC maturation, CD8+ TIL, Treg reduction

Kisspeptin-10

Anti-metastatic / anti-angiogenic

SKOV-3-luc i.p. xenograft

KISS1R-Gαq-MMP inhibition, peritoneal implant reduction

Follistatin

Activin A neutralisation / TME

OVCAR-3, ID8

SMAD2/3-MMP-2, CD8+ TIL restoration

GHK-Cu

Anti-proliferative / cisplatin sensitisation

A2780, SKOV-3

MMP-2/9 suppression, Nrf2-HO-1, G1 arrest

MOTS-C

Metabolic reprogramming / omentum

ID8 obese mouse, ES-2

AMPK-FAO axis, FABP4, adipokine reduction

Epitalon

Chemoprevention / telomere

ENU rat model

Melatonin restoration, oestrogen rhythm, 8-OHdG

BPC-157

TME / platinum toxicity research

Peritoneal adhesion, cisplatin-AKI

FAK-eNOS-VEGF, TNF-α/IL-6 reduction, ZO-1

LL-37

FPRL1 biology / TME (pro-tumorigenic)

OVCAR-3, SKOV-3

FPRL1-PI3K-Akt, ascites autocrine loop (research target)

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Thymosin Alpha-1, Kisspeptin-10, Follistatin, GHK-Cu, MOTS-C, Epitalon, BPC-157, and LL-37 for research and laboratory use. View UK stock →

Conclusion

Ovarian cancer research with peptide compounds spans several mechanistically distinct domains: Thymosin Alpha-1 addresses the immunosuppressive TME through TLR9/DC priming and CD8+ TIL restoration; Kisspeptin-10 suppresses peritoneal dissemination via KISS1R-mediated MMP inhibition; Follistatin neutralises tumour-promoting activin A and restores CD8+ immunity; GHK-Cu provides anti-proliferative and cisplatin-sensitising biology; MOTS-C disrupts omentum-dependent FAO metabolism driving peritoneal seeding; and Epitalon offers chemoprevention-relevant telomere and antioxidant biology. LL-37 represents an important research target as a pro-tumorigenic TME factor in ovarian cancer contexts. Each operates through a distinct mechanistic axis, reflecting the molecular heterogeneity of HGSOC biology and providing multiple non-overlapping research angles for preclinical investigation.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like